The global Vaccine Conjugate market size was valued at US$ 10900 million in 2024 and is forecast to a readjusted size of USD 13570 million by 2031 with a CAGR of 3.2% during review period.
Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.
North America is the largest supplier of Conjugate Vaccine, with a production market share nearly 65. Europe is the second largest supplier of Conjugate Vaccine, enjoying production market share nearly 26.
This report is a detailed and comprehensive analysis for global Vaccine Conjugate market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Vaccine Conjugate market size and forecasts, in consumption value ($ Million), sales quantity (K Doses), and average selling prices (US$/Dose), 2020-2031
Global Vaccine Conjugate market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Doses), and average selling prices (US$/Dose), 2020-2031
Global Vaccine Conjugate market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Doses), and average selling prices (US$/Dose), 2020-2031
Global Vaccine Conjugate market shares of main players, shipments in revenue ($ Million), sales quantity (K Doses), and ASP (US$/Dose), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Vaccine Conjugate
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Vaccine Conjugate market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, GSK, Sanofi, Merck, Walvax Biotechnology, Royal (Wuxi) Bio-Pharmaceutical, Bharat Biotech, Zhifei Biologic, Chengdu Olymvax Biopharmaceuticals, Beijing Minhai Biotechnology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Vaccine Conjugate market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Hib Vaccine
Meningococcal Vaccine
Pneumococcal Vaccine
Others
麻豆原创 segment by Application
Children
Adult
Major players covered
Pfizer
GSK
Sanofi
Merck
Walvax Biotechnology
Royal (Wuxi) Bio-Pharmaceutical
Bharat Biotech
Zhifei Biologic
Chengdu Olymvax Biopharmaceuticals
Beijing Minhai Biotechnology
CanSinoBIO
Beijing Xiangrui Biological Products
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Vaccine Conjugate product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Vaccine Conjugate, with price, sales quantity, revenue, and global market share of Vaccine Conjugate from 2020 to 2025.
Chapter 3, the Vaccine Conjugate competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Vaccine Conjugate breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Vaccine Conjugate market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Vaccine Conjugate.
Chapter 14 and 15, to describe Vaccine Conjugate sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Vaccine Conjugate Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Hib Vaccine
1.3.3 Meningococcal Vaccine
1.3.4 Pneumococcal Vaccine
1.3.5 Others
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Vaccine Conjugate Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Children
1.4.3 Adult
1.5 Global Vaccine Conjugate 麻豆原创 Size & Forecast
1.5.1 Global Vaccine Conjugate Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Vaccine Conjugate Sales Quantity (2020-2031)
1.5.3 Global Vaccine Conjugate Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Vaccine Conjugate Product and Services
2.1.4 Pfizer Vaccine Conjugate Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Pfizer Recent Developments/Updates
2.2 GSK
2.2.1 GSK Details
2.2.2 GSK Major Business
2.2.3 GSK Vaccine Conjugate Product and Services
2.2.4 GSK Vaccine Conjugate Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 GSK Recent Developments/Updates
2.3 Sanofi
2.3.1 Sanofi Details
2.3.2 Sanofi Major Business
2.3.3 Sanofi Vaccine Conjugate Product and Services
2.3.4 Sanofi Vaccine Conjugate Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Sanofi Recent Developments/Updates
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck Vaccine Conjugate Product and Services
2.4.4 Merck Vaccine Conjugate Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Merck Recent Developments/Updates
2.5 Walvax Biotechnology
2.5.1 Walvax Biotechnology Details
2.5.2 Walvax Biotechnology Major Business
2.5.3 Walvax Biotechnology Vaccine Conjugate Product and Services
2.5.4 Walvax Biotechnology Vaccine Conjugate Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Walvax Biotechnology Recent Developments/Updates
2.6 Royal (Wuxi) Bio-Pharmaceutical
2.6.1 Royal (Wuxi) Bio-Pharmaceutical Details
2.6.2 Royal (Wuxi) Bio-Pharmaceutical Major Business
2.6.3 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product and Services
2.6.4 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments/Updates
2.7 Bharat Biotech
2.7.1 Bharat Biotech Details
2.7.2 Bharat Biotech Major Business
2.7.3 Bharat Biotech Vaccine Conjugate Product and Services
2.7.4 Bharat Biotech Vaccine Conjugate Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Bharat Biotech Recent Developments/Updates
2.8 Zhifei Biologic
2.8.1 Zhifei Biologic Details
2.8.2 Zhifei Biologic Major Business
2.8.3 Zhifei Biologic Vaccine Conjugate Product and Services
2.8.4 Zhifei Biologic Vaccine Conjugate Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Zhifei Biologic Recent Developments/Updates
2.9 Chengdu Olymvax Biopharmaceuticals
2.9.1 Chengdu Olymvax Biopharmaceuticals Details
2.9.2 Chengdu Olymvax Biopharmaceuticals Major Business
2.9.3 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Product and Services
2.9.4 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Chengdu Olymvax Biopharmaceuticals Recent Developments/Updates
2.10 Beijing Minhai Biotechnology
2.10.1 Beijing Minhai Biotechnology Details
2.10.2 Beijing Minhai Biotechnology Major Business
2.10.3 Beijing Minhai Biotechnology Vaccine Conjugate Product and Services
2.10.4 Beijing Minhai Biotechnology Vaccine Conjugate Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Beijing Minhai Biotechnology Recent Developments/Updates
2.11 CanSinoBIO
2.11.1 CanSinoBIO Details
2.11.2 CanSinoBIO Major Business
2.11.3 CanSinoBIO Vaccine Conjugate Product and Services
2.11.4 CanSinoBIO Vaccine Conjugate Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 CanSinoBIO Recent Developments/Updates
2.12 Beijing Xiangrui Biological Products
2.12.1 Beijing Xiangrui Biological Products Details
2.12.2 Beijing Xiangrui Biological Products Major Business
2.12.3 Beijing Xiangrui Biological Products Vaccine Conjugate Product and Services
2.12.4 Beijing Xiangrui Biological Products Vaccine Conjugate Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Beijing Xiangrui Biological Products Recent Developments/Updates
3 Competitive Environment: Vaccine Conjugate by Manufacturer
3.1 Global Vaccine Conjugate Sales Quantity by Manufacturer (2020-2025)
3.2 Global Vaccine Conjugate Revenue by Manufacturer (2020-2025)
3.3 Global Vaccine Conjugate Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Vaccine Conjugate by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Vaccine Conjugate Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Vaccine Conjugate Manufacturer 麻豆原创 Share in 2024
3.5 Vaccine Conjugate 麻豆原创: Overall Company Footprint Analysis
3.5.1 Vaccine Conjugate 麻豆原创: Region Footprint
3.5.2 Vaccine Conjugate 麻豆原创: Company Product Type Footprint
3.5.3 Vaccine Conjugate 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Vaccine Conjugate 麻豆原创 Size by Region
4.1.1 Global Vaccine Conjugate Sales Quantity by Region (2020-2031)
4.1.2 Global Vaccine Conjugate Consumption Value by Region (2020-2031)
4.1.3 Global Vaccine Conjugate Average Price by Region (2020-2031)
4.2 North America Vaccine Conjugate Consumption Value (2020-2031)
4.3 Europe Vaccine Conjugate Consumption Value (2020-2031)
4.4 Asia-Pacific Vaccine Conjugate Consumption Value (2020-2031)
4.5 South America Vaccine Conjugate Consumption Value (2020-2031)
4.6 Middle East & Africa Vaccine Conjugate Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Vaccine Conjugate Sales Quantity by Type (2020-2031)
5.2 Global Vaccine Conjugate Consumption Value by Type (2020-2031)
5.3 Global Vaccine Conjugate Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Vaccine Conjugate Sales Quantity by Application (2020-2031)
6.2 Global Vaccine Conjugate Consumption Value by Application (2020-2031)
6.3 Global Vaccine Conjugate Average Price by Application (2020-2031)
7 North America
7.1 North America Vaccine Conjugate Sales Quantity by Type (2020-2031)
7.2 North America Vaccine Conjugate Sales Quantity by Application (2020-2031)
7.3 North America Vaccine Conjugate 麻豆原创 Size by Country
7.3.1 North America Vaccine Conjugate Sales Quantity by Country (2020-2031)
7.3.2 North America Vaccine Conjugate Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Vaccine Conjugate Sales Quantity by Type (2020-2031)
8.2 Europe Vaccine Conjugate Sales Quantity by Application (2020-2031)
8.3 Europe Vaccine Conjugate 麻豆原创 Size by Country
8.3.1 Europe Vaccine Conjugate Sales Quantity by Country (2020-2031)
8.3.2 Europe Vaccine Conjugate Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Vaccine Conjugate Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Vaccine Conjugate Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Vaccine Conjugate 麻豆原创 Size by Region
9.3.1 Asia-Pacific Vaccine Conjugate Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Vaccine Conjugate Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Vaccine Conjugate Sales Quantity by Type (2020-2031)
10.2 South America Vaccine Conjugate Sales Quantity by Application (2020-2031)
10.3 South America Vaccine Conjugate 麻豆原创 Size by Country
10.3.1 South America Vaccine Conjugate Sales Quantity by Country (2020-2031)
10.3.2 South America Vaccine Conjugate Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Vaccine Conjugate Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Vaccine Conjugate Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Vaccine Conjugate 麻豆原创 Size by Country
11.3.1 Middle East & Africa Vaccine Conjugate Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Vaccine Conjugate Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Vaccine Conjugate 麻豆原创 Drivers
12.2 Vaccine Conjugate 麻豆原创 Restraints
12.3 Vaccine Conjugate Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Vaccine Conjugate and Key Manufacturers
13.2 Manufacturing Costs Percentage of Vaccine Conjugate
13.3 Vaccine Conjugate Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Vaccine Conjugate Typical Distributors
14.3 Vaccine Conjugate Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Pfizer
GSK
Sanofi
Merck
Walvax Biotechnology
Royal (Wuxi) Bio-Pharmaceutical
Bharat Biotech
Zhifei Biologic
Chengdu Olymvax Biopharmaceuticals
Beijing Minhai Biotechnology
CanSinoBIO
Beijing Xiangrui Biological Products
听
听
*If Applicable.
